Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03333486 · OUTCOME

Proportion of Participants With Acute Graft Versus Host Disease (GVHD)

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer · Source last updated 2025-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
At 100 days post-transplant

What was measured

Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson.

Analysis population: All treated and eligible patients

Groups in this outcome

Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)

Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0. Cyclophosphamide: Given IV Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Peripheral Blood Stem Cell Transplantation: Undergo PBSCT Total-Body Irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)31

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)0.3226Not reported0.16680.5137Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.1668
        upper Limit
        0.5137
        value
        0.3226
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
Will be computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0. Cyclophosphamide: Given IV Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Peripheral Blood Stem Cell Transplantation: Undergo PBSCT Total-Body Irradiation: Undergo TBI
    id
    OG000
    title
    Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)
param Type
NUMBER
population Description
All treated and eligible patients
reporting Status
POSTED
time Frame
At 100 days post-transplant
title
Proportion of Participants With Acute Graft Versus Host Disease (GVHD)
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice